Neuralight had its brain-function biomarkers selected for the Healthy Brain Ageing (HeBA) initiative, a European program tracking nearly 13,000 adults. The company measures core aspects of brain function from video using an AI engine, turning eye and facial movement into quantitative markers that can detect change up to a decade before symptoms appear. The deployment places Neuralight's platform inside one of the larger population-scale brain health studies, extending its work from drug trials into long-term population monitoring.

NeuraLight and Kariya Pharmaceuticals announced a partnership to bring NeuraLight's eye-tracking biomarker platform into Kariya's Phase II program for KP405, a brain-penetrant GLP-1 agonist being developed for Parkinson's and Alzheimer's disease. For NeuraLight, the partnership places its platform within the measurement layer of the GLP-1/neurodegeneration thesis, where more precise biomarkers are needed to track whether popular peptide therapies are actually reaching and protecting the brain.